Clinical Trial Update: Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial assessing durvalumab in combination with olaparib and/or cediranib for advanced solid tumors, including colorectal and breast neopla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer

Drugs mentioned

• Cediranib (Cediranib)
• Durvalumab (Imfinzi) (durvalumab)
• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colorectal Neoplasms, Breast Neoplasms | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING